Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients

Sponsor
Sanofi
Study ID
NCT00271271
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Primary: ·To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer Secondary: ·To evaluate the toxicity of the combination

Key Dates

Start date
Jun 30, 2003
Status verified
Dec 2009
Completion
Oct 31, 2006

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Objective rate of response (ORR) according to the RECIST criterion, as evaluated by a review panel of outside experts.

Related Studies